Amedisys (AMED) Prelim. Q3 EPS Misses Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Wall Street closes higher as investors digest earnings, megacap outlook
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
Amedisys Previews Third Quarter 2016 Results
October 27, 2016 8:00 AM EDTBATON ROUGE, La., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), one of Americas leading home health and hospice care companies, today announced preliminary financial results for the third quarter ended September 30, 2016. These preliminary results are subject to completion of the Companys quarterly financial and accounting procedures.Â
Amedisys anticipates quarterly revenue of approximately $362 million and net income attributable to Amedisys, Inc. per diluted share between $0.33 and $0.35 on a GAAP basis. On an adjusted basis, net income attributable to Amedisys, Inc. per diluted share for the quarter is anticipated to be between $0.35 and... More
